George L. Drusano, MD

Dr. George L. Drusano is director of the Institute for Therapeutic Innovation at the University of Florida. After graduating magna cum laude, ΦΒΚ from the honors program at Boston College, Drusano graduated cum laude, ΑΩΑ from the University of Maryland School of Medicine in Baltimore. He completed his medical internship and residency at the University of Maryland Hospital, where he was chief medical resident. He was also a fellow in Medicine in Infectious Diseases at that institution. Drusano is a reviewer for various peer-reviewed journals, including Science-Translational Medicine, New England Journal of Medicine, the Annals of Internal Medicine, Archives of Internal Medicine, American Journal of Medicine, Journal of Infectious Diseases, the Journal of Antimicrobial Chemotherapy and Antiviral Research. He was also editor of the section of pharmacology and experimental therapeutics for Antimicrobial Agents and Chemotherapy for 10 years. He is currently an editor for mBio. He is the author of over 300 articles in peer-reviewed journals such as the Journal of Clinical Investigation, Nature Reviews Microbiology, Journal of the American Medical Association, Annals of Internal Medicine, Journal of Infectious Diseases, Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy, AIDS, Clinical Pharmacology and Therapeutics, Journal of Clinical Pharmacology and Diagnostic Microbiology and Infectious Diseases. Drusano is a fellow of the Infectious Diseases Society of America. On the national level, he was a member of the Interscience Conference on Antimicrobial Agents and Chemotherapeutics (ICAAC) Program Committee and the IDSA Program Committee. He has served on multiple National Institute of Allergy and Infectious Diseases (NIAID) Review Groups. He has served as an ad hoc member of NIAID Council on two occasions to support issues regarding emergence of bacterial resistance. He also serves as a consultant to NIAID and CDC on Biodefense issues. In 2010, Drusano was chair of the Gordon Conference on New Antimicrobial Discovery and Development. He has won a number of awards, including being named Distinguished Investigator of the Year (2003) by the American College of Clinical Pharmacology. He was named recipient of the Maxwell Finland Award for Scientific Achievement for 2012 from the National Foundation for Infectious Diseases. He was also named the recipient of the Cubist-ICAAC award for 2013 from the American Society for Microbiology. Most recently, he was awarded the Paul Ehrlich Magic Bullet Award in 2015. An active researcher, Drusano has focused on mathematical modeling and the pharmacodynamics of anti-infective chemotherapy, especially the pharmacodynamics of anti-tuberculosis agents, MDR/XDR nosocomial pathogens, multiple anti-viral agents and the therapy of biodefense pathogens. He has been awarded a Program Project Grant from NIAID “Choosing Drug Doses for Biodefense Pathogens,” R01’s from NIAID for “Resistance Suppression for P. aeruginosa using Novel Combination Therapy Modeling,” Optimizing Combination Therapy for Hepatitis C virus with pharmacodynamic models and an R01 for drug development “Optimization of Neoglycoside Antibiotics for Nosocomial Pathogens and Select Agents.” Most recently, Drusano was awarded a P01 from NIAID “Optimizing Combination Therapy to Accelerate Clinical Cure of Tuberculosis”.